RBC keeps AngioDynamics at outperform

AngioDynamics Inc. was kept at outperform, speculative risk, and a $30 price target by RBC Capital Markets analyst Phil Nalbone ahead of the company's announcement of August-quarter results. The analyst expects first-quarter revenue growth of 23.3% to $20.2 million and flat earnings per share of $0.10. The Street estimates sales of $20.04 million and earnings per share of $0.10. If management maintains previous guidance and executes according to plan, RBC believes confidence will be restored and the stock should continue to trade higher. Shares of the Queensbury, N.Y.-based medical device company were up 80 cents, or 3.22%, at $19.25. (Nasdaq: ANGO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.